$KYMRIAH is indicated for the treatment of paediatric and young adult patients aged 3 to 25 years with relapsed or refractory B-cell acute lymphoblastic leukaemia and adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant.$

For Health Care Professionals Outside the US

US Residents
KYMRIAH Product Characteristics
Safety Information
Order KYMRIAH

Find a Centre

DLBCL
- ALL
Efficacy
Safety
- Managing
  Adverse Reactions
- Most Common
  Adverse Reactions
CAR-T Technology
- About KYMRIAH
- Mechanism of Action
Treatment
Qualified Centres

ALL
- DLBCL
Efficacy
Safety
- Managing
  Adverse Reactions
- Most Common
  Adverse Reactions
CAR-T Technology
- About KYMRIAH
- Mechanism of Action
Treatment
Qualified Centres

Site Map

Gateway

DLBCL
ALL

DLBCL

Efficacy
Safety
- Managing Adverse Reactions
- Most Common Adverse Reactions
CAR-T Technology
- About KYMRIAH
- Mechanism of Action
Treatment
Qualified Centres

ALL

Efficacy
Safety
- Managing Adverse Reactions
- Most Common Adverse Reactions
CAR-T Technology
- About KYMRIAH
- Mechanism of Action
Treatment
Qualified Centres

KYMRIAH Product Characteristics

Safety Information

Site Map

Privacy
Site Map
Contact Us
Summary of Product Characteristics
Safety Information
Cookie Settings

Disclaimer: This is an international website for KYMRIAH and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC).

You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.

Cancel

Continue

Coming soon
A list of qualified treatment centres near you

This is an international site for KYMRIAH^® (tisagenlecleucel) and is intended for health care professionals (HCPs) outside the US.

Welcome to KYMRIAH^® (tisagenlecleucel)

Health Care Professionals
Patients

I am a Health Care Professional outside the US
Enter site

The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local Novartis representative for local prescribing information via https://www.novartis.com/our-company/contact-us

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)

US HCPs & Other
Country-Specific Websites

Here is a list of the countries that host a KYMRIAH website based on local label and in a local language. Each website is intended for HCPs only. If you are an HCP from one of the countries listed below, click on your country’s link to be redirected to your country’s KYMRIAH website.

Choose Country

United States

I am a Patient Inside the US
I am a Patient Outside the US

You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.

Cancel

Continue

You are now leaving KYMRIAH.com and will be redirected to Novartis.com to review the press release.

Cancel

Continue